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ABSTRACT Background	Immune	cells	promote	periodontal	bone	loss	through	an	unresolved	inflammatory	response	to	bacterial	pathogens.	The	limited	availability	of	ex	vivo	gingival	immune	cells	severely	impedes	identification	of	cell	types	and	cell-specific	functions	that	drive	human	periodontitis	and	thus	impedes	the	development	of	effective	pharmacotherapeutics.		Previous	studies	have	largely	relied	on	mRNA	analysis	and	confocal	microscopy	to	imprecisely	estimate	gingival	immune	cell	function.	The	aim	of	the	study	was	to	develop	a	cell	type-specific	technique	to	quantitate	function	of	resident	gingival	immune	cells.		Methods	Diseased	tissues	from	chronic	periodontitis	in	non-diabetes	or	type	2	diabetes	subjects	or	relatively	healthy	gingival	tissues	were	removed	during	standard-of-care	surgery	for	pocket	reduction	surgery	or	crown	lengthening,	respectively.	Gingiva	was	dissociated	with	collagenase	to	generate	single	cell	suspensions,	then	9-color	flow	cytometry	was	used	quantitate	and/or	isolate	myeloid	cells	(CD11b+),	B	cells	(CD20+),	T	cells	(CD4+	or	CD8+)	and	natural	killer	(NK)	cells	(CD56+).	We	stimulated	the	sorted	cells	with	lineage-appropriate	activators	for	36	hrs	and	measured	cytokine	production	by	ELISPOT,	an	assay	that	identifies	individual	cytokine-producing	cells	by	fixed	“spots”	on	a	solid	support.			Results		A	higher	proportion	of	gingival	CD4+	T	helper	cells	and	not	CD8+cytoxic	T	cells	from	subjects	with	periodontal	disease	with	or	without	type	2	diabetes	produce	pro-inflammatory	cytokines	compared	to	CD4+	T	cells	from	crown	lengthening	subjects.	CD4+	T	cells	were	the	dominant	cell	population	in	gingiva	from	all	three	groups,	and	all	groups	contained	similar	proportions	of	cytotoxic	(CD8+)	T	cells,	myeloid	cells	(CD11b+),	B	cells	(CD20+)	and	natural	killer	cells	(CD56+).			
		 vi 
			Conclusion	The	combination	of	flow	cytometry,	cell	sorting	and	ELISPOT	identified	CD4+	T	cells	as	dominant	immune	cells	in	human	periodontal	lesions,	and	identified	T	cell	cytokines	that	may	uniquely	promote	periodontitis	in	type	2	diabetes.	
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Chapter one: Cross talk amongst chronic inflammatory diseases 
Introduction 
Chronic inflammatory diseases like diabetes, obesity, arthritis and periodontitis (PD) are 
prevalent in the human population.   Interrelationships amongst these diseases make 
understanding of cause and effect challenging. Obesity generally promotes metabolic 
disturbances, although about 11% of obese people remain metabolically healthy (Denis 
and Obin 2013). Similarly, subjects with T2D have 2.8-3.4 fold increased risk of having 
PD (Mealey 2006).   One strategy to understanding the etiology of overlapping diseases 
is the practical difficulty of completing longitudinal studies with the correct controls that 
record as much information about the patient as possible e.g. %HbA1c (a measure of 
glycemic control), BMI, waist circumference, periodontal status, lipid profiles etc.  
 
The latest American Diabetes Association report about diagnosis and classification of 
diabetes confirms that obesity is a risk factor for diabetes as well as one of their criteria 
for diagnosing pre-diabetes (ADA 2015).   Our current understanding about relationships 
amongst obesity, diabetes and periodontitis remains vague.  
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Section one: Diabetes is a risk factor for periodontitis 
Diabetes has been extensively studied as a risk factor for periodontitis. (Cohen et al. 
1970; Novaes, Gutierrez, and Novaes 1996). (Campus et al. 2005) observed greater 
attachment loss in (T2D) subjects when compared to age matched non-diabetics (ND) 
subjects (Soskolne and Klinger 2001) identified the same risk in the Korean population. 
Analyzing the Korea National Health and Nutrition Examination Survey (KNHANES) III 
data, they concluded that in addition to the convincing epidemiological evidence that PD 
is more prevalent among those with diabetes. Furthermore, the prevalence of diabetes in 
those with PD is significantly greater (2 fold) than in those without PD. Thus, as the 
authors state, “The epidemiological associations between periodontitis and diabetes could 
be the result of at least two similar but distinct pathogenic pathways: a direct causal 
relationship in which the consequences of diabetes act as modifiers of periodontal disease 
or, alternatively, a common pathological defect that results in a host susceptible to either, 
or both, diseases”.  
 
Direct causal relationship between diabetes and periodontitis remains controversial. 
(Engebretson et al. 2013) found that nonsurgical periodontal treatment had no effect on 
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A1c levels of (T2D) patients. However critiques of this study were numerous. For 
example, the mean HbA1c reported was 7.8 with 60% of the subjects less than 8%. This 
HbA1c is so close to the therapeutic target that the little effect of non-surgical 
intervention would be expected. Another weakness was that the effect of periodontal 
health improvement did not meet the consensus for reported outcomes (Van der Weijden 
and Timmerman 2002) with residual plaque level of 72% and bleeding scores 42% after 
therapy. 
 
 
Section two: Obesity as a risk factor for periodontitis 
Multiple studies have shown a positive association between obesity and PD regardless of 
the metabolic state. (Bandyopadhyay et al. 2010) studied the prevalence of PD in well-
controlled vs. poorly-controlled obese T2D subjects and found more aggressive 
progression in pocket probing depth and clinical attachment loss (CAL) in cases of poor 
glucose control.  They also found that a high BMI was associated with a greater risk of 
harboring periodontal pockets, indicating that obesity may have T2D-indpendents effects 
The hypothesis that obesity and periodontitis are correlated has been reviewed by 
(Chaffee and Weston 2010). They reviewed evidence from studies associating obesity 
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and periodontitis and concluded that obesity and periodontitis are positively correlated. 
However they were unable to pinpoint the direction of this relationship. (Kim, Jin, and 
Bae 2011) used KNHANES-IV data to evaluate the relationship between PD and waist 
circumference in the Korean population. When sex, ethnicity, education level, poverty 
index, smoking, diabetes, and elapsed time since their last dental visit were matched, high 
waist circumference presented higher odds ratio (1.358) for the presence of PD compared 
to BMI alone (0.991). Saxlin et al similarly studied a population in Finland in which they 
used BMI as a cut off between obese and non-obese. This study also a positive 
correlation between obesity and periodontitis as well. (Saxlin et al. 2011) 
 
Section three: Periodontal disease associated with Metabolic syndrome 
Metabolic syndrome a pro-inflammatory state characterized by insulin resistance, central 
obesity, elevated triglycerides, decreased high density lipoproteins (HDL), hypertension 
and increased oxidative stress (Gallagher, Leroith, and Karnieli 2011) that often follows 
from obesity. prevalence of metabolic syndrome in the U.S is 34.6% with equal risk for 
males and females. It is characterized by low grade inflammation indicated by increased 
C reactive proteins and fibrinogen (Wannamethee et al. 2005). It shares risk factors with 
periodontitis such as hyperglycemia and dyslipidemia (Gurav 2014). People with 
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metabolic syndrome are more susceptible to PD (Benguigui et al. 2010; Han et al. 2012; 
Iwasaki et al. 2015)	, confirming the correlation between the two diseases. However it has 
not been confirmed whether it is a causal effect or only shared common risk factors with 
periodontitis redundant removed (Gurav 2014). 
 
Section four: Effect of Periodontal therapy on Glycemic control 
Two major reviews (Teeuw, Gerdes, and Loos 2010; Simpson et al. 2010) arrived at the 
same conclusion: periodontal treatment with or without co-treatment with antibiotics 
improves glycemic control, albeit modestly (a 0.4% decrease in HbA1c). This modest 
reduction is nonetheless clinically significant given that every 0.2% improvement in A1c 
is associated with 10% decrease in diabetes mortality (Khaw et al. 2004). However not all 
studies support an improvement in glycemic control following periodontal treatment. 
(Faria-Almeida, Navarro, and Bascones 2006) measured A1c of T2D diabetes subjects 
after non-surgical periodontal therapy at 3 and 6 months. They showed a slight, but 
clinically insignificant reduction in A1c, in subjects with %HbA1c within the “well-
controlled T2D” range. Engbretson and co-authors studied HbA1c level in 257 T2D 
patients before and after non-surgical therapy and comparing them to 257 T2D patients 
without cleaning as a control group after 6 months. They concluded that there was no  
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clinical improvement in Hba1c level of 0.05. Therefor due to variability of research 
findings this topic is still controversial and needs further investigations (Engbretson, et al 
2013).  
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Chapter two: Periodontal disease Pathogenesis: local and systemic 
Introduction 
In periodontal disease (PD), the underlying cause of increased pathogenic serum lipids 
and insulin resistance is related to invasion of Gram negative bacteria through the dento-
gingival junction which may reach 39 cm2 in periodontal disease (Nesse et al. 2008). PD 
thereby acts as a local focal point of chronic infection that likely fuels a vicious cycle of 
dyslipidemia and insulin resistance (Cutler et al. 1999; Losche et al. 2000). To understand 
how periodontitis affects lipid profiles we will first discuss a crucial role of the 
microbiome. 
 
Section One: The role of bacteria in igniting periodontal disease 
The human body harbors of bacterial strains. Under homoeostatic conditions these 
bacteria are commensal, but any disruption in either the host response or the bacterial 
distribution may lead to disease. The NIH/ National Human Genome institute started an 
initiative “Human Microbiome Project” in 2008 (Human Microbiome Jumpstart 
Reference Strains et al. 2010) to assess the microbial changes in healthy and diseased 
status by microbial DNA sequencing. They defined the main areas of interaction between 
bacteria and host as the nose, oral cavity, gut, skin, and vagina. 
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Imbalance of the microbiome has long been believed to cause PD. In 1980 it was 
generally thought that periodontal disease is purely due to the specific bacterial 
pathogenesis i.e. the “Specific plaque hypothesis”. Our more recent understanding of 
periodontal disease is more dynamic and is based on a model of deregulated microbial-
host interaction. (Hajishengallis and Lamont 2014) introduced the model of 
polymicrobial synergy and dysbiosis (PSD) as a new way to think about PD. This model 
suggests that bacteria work in synergy to allow the fittest to survive and perpetuate the 
imbalance between bacteria and host-immune response. 
 
Section two: Systemic distribution of Oral bacteria 
Oral pathogens can affect the systemic health by directly invading the peridontium then 
leaking through gingival ulceration to cause systemic bacteremia (Tomas et al. 2012). 
This pathway was confirmed by (Geerts et al. 2002) who showed that serum levels of 
endotoxins were increased after masticating one apple. In addition, (Lee et al. 2008) 
reported that endotoxemia occurs 5 min after periodontal deep cleaning which justifies 
prophylactic antibiotics prior to the procedure. 
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Periodontal pathogens that drive periodontal disease in lean/healthy people also colonize 
T2D patients with severe periodontitis yet T2D patients almost always present with more 
aggressive forms of bone loss (Zambon et al. 1988; Thorstensson, Dahlen, and Hugoson 
1995; Sbordone et al. 1998). For example, patients with (T2D) showed more aggressive 
disease progression than non-diabetics (ND) in a study in which oral hygiene for 3 weeks 
to allow developent gingivitis (Salvi et al. 2005).  
 
Section three: Signature Cytokines in periodontal pathology and their effect 
on adipose tissue, inflammation and insulin resistance 
 
Bacterial dysbiosis underlies a pro-inflammatory state and alters cytokine production by 
leukocytes, the major stimulators of inflammation in PD and T2D. In 2007 Gemmel et al. 
described the role of cytokines as fulcrum between homeostasis  and progression of 
periodontal disease in the presence of bacteria (Gemmell, Yamazaki, and Seymour 2007). 
We will discuss cytokines roles in both adipose tissue-associated inflammation and 
periodontal disease that may link the pathologies to the known association in obesity-
associated T2D and PD. 
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TNFα 
The pathogenicity of TNFα appears early in periodontal disease when it stimulates cell 
adhesion (Kindle et al. 2006). Moreover TNFα expression is correlated with increases in 
Matrix-metalloproteinase (MMPs) and RANKL which are two proteins known to cause 
periodontal bone loss (Garlet et al. 2004; Graves et al. 2008). TNFα was elevated in 
serum of subjects with severe periodontitis (Nishimura et al. 2003) but was reduced after 
periodontal treatment (Iwamoto et al. 2001), indicating systemic repercussion of these 
locally triggered events. (Lalla et al. 2007) Similarly showed periodontal therapy reduced 
TNFα cocnentrations in peripheral blood. (Genco et al. 2005) also showed direct 
correlation between periodontal disease and serum TNFα levels in people with BMI < 
24.6. 
 
In addition to the link with PD, TNFα is very strongly correlated with obesity-associated 
insulin resistance and is directly correlated with the abdominal (generally unhealthy) fat 
to peripheral (generally healthy) fat ratio (Tsigos et al. 1999). Perhaps the strongest 
example of a role for TNFα in a T2D-like disease in mice is the demonstration  
that TNFα knockout mice were protected against obesity-induced insulin resistance 
(Uysal et al. 1997) despite maintaining fat mass similar to wild-type mice. Two suggested 
		 11	
mechanisms by which TNFα induces insulin resistance are 1. by blocking insulin receptor 
substrate 1 (IRS-1), thus blocking glucose transportation proteins (GLUT-4) and 
impairing insulin action (Paz et al. 1997); and 2. IRS-1 directly damages the beta cells in 
the pancreas. TNFα also potentiates production of IL-1β and synergizes with this 
classical diabetogenic cytokine in a feed-forward cycle of obesity-associated 
inflammation (Kwak et al. 2005); (Musacchio et al. 2009).  
 
IL-1β 
 
Like TNFα, IL-1β has broad systemic as well as local inflammatory effects. The 
consensus is that IL-1β is elevated in periodontal disease based on found elevated IL-1β, 
among multiple biomarkers, in gingival crevicular fluid (GCF) of periodontal disease 
patients (Kinney et al. 2014).  IL-1β is also increased in diabetes wherein hyperglycemia 
induces IL-1β to activate NF-kB, a major contributor to inflammatory pathways (Maedler 
et al. 2002). The function of IL-1β is further exacerbated by the abnormally low 
production of the IL-1β receptor antagonist compared with ND (Maedler et al. 2004). A 
direct link between IL-1β and insulin resistance has been indicated by IL-1β blocking 
antibody which was shown to protect mice from diet-induced (T2D) (Osborn et al. 2008; 
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Sauter et al. 2008), although clinical trials have had less spectacular outcomes (Larsen et 
al. 2009). Downstream effects of IL-1β include initiation of IL-6 inflammatory cascade 
(Jura et al. 2008) further increasing its pro-inflammatory role in T2D. 
 
IL-6  
IL-6 is known to be inflammatory in periodontal disease. Studies have shown that IL-6 
leaks into the bloodstream (Ide et al. 2003; Loos et al. 2000). , as indicated by cross-
sectional studies showing a correlation between periodontitis and the aforementioned 
diseases.  
Immunometabolism research showed that IL-6 is a major contributor to inflamed adipose 
tissue in obesity.  In general, serum IL-6 is higher in T2D than in Non-T2D (ND) and, 
although multiple cell types make IL-6, T cells and myeloid cells, rather than B cells, are 
most likely sources for obesity-associated increases (Jagannathan et al. 2010)(F. Raval, 
unpublished observation). Activated adipocytes from subcutaneous adipose tissue may 
also be responsible for overabundance of IL-6 in T2D (Mohamed-Ali et al. 1997).  The 
pro-inflammatory functions of IL-6 are numerous. IL-6 inhibits the CD4+ Th2 
lymphocyte proliferation thus decreasing net concentrations of Th2-signature anti-
inflammatory cytokines such as IL-4, IL-5, IL-13 (Mayer et al. 2014). IL-6 also directly 
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effects glucose metabolism in skeletal muscle (Pickup et al. 2000; Kristiansen and 
Mandrup-Poulsen 2005). A downstream effect of IL-6 is to stimulate a newly identified 
diabetogenic T cell subset, Th17 by inducing IL-17 production (Acosta-Rodriguez et al. 
2007). 
 
IL-17a 
The T cell subpopulation Th17 produces IL-17. Th17 population increases in with 
obesity and T2D and therefore the IL-17 load is increased. It induces many inflammatory 
pathways, one of which is NF-kB (Onishi and Gaffen 2010). It also stimulates G-CSF to 
attract more neutrophils to the inflamed tissues (Kolls and Linden 2004). IL-17a directly 
induced insulin resistance in muscle, adipose tissue and liver (Fabbrini et al. 2013). The 
Nikolajczyk lab recently demonstrated that a comprehensive Th17 signature dominates T 
cell-mediated inflammation in T2D (Ip et al 2016). Given that Th17a’s also support 
inflammation in PD, this recent work suggests that these cell may be critical mediators of 
T2D/PD association. 
 
IL-8 
IL-8, also known as “CXCL8”, is a chemotactic factor for neutrophils. IL-8 is secreted by 
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inflamed adipocytes, fibroblasts, gingival epithelium and endothelial cells (Takigawa et 
al. 1994; Takashiba et al. 1992), and has direct stimulatory effects on osteoclasts (Bendre 
et al. 2003). Although myeloid cells are classical sources of IL-8, B cells from PD or 
T2D subjects secrete significant amounts of IL-8 in response to toll-like receptor 
stimulation (Jagannathan et al. 2010). Our knowledge of IL-8 is limited especially with 
the emerging paradigm of pro-inflammatory resolution introduced by Dr. Van Dyke and 
Dr. Charles Serhan. The new paradigm suggests that IL-8- mediated neutrophil 
infiltration is not in itself harmful but failure to phagocytize the injured tissue aftermath 
by macrophages causes the inflammation. 
 
 
IL-10 and IL-4 
IL4 and IL-10 are generally considered anti-inflammatory cytokines. IL-4 suppresses IL-
6, TNFα and IL-1β production (Essner et al. 1989). The effect of IL-4 to reduce clinical 
inflammation in DBA/1 transfected fibroblasts to was much greater than OPG in 
collagen-induced arthritis. (Sasaki et al. 2004)Showed that IL-10-/- mice are more 
susceptible to periodontal bone loss supporting complementary work that demonstrated  
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IL-4 and IL-10 decrease bone resorption (Saidenberg-Kermanac'h et al. 2004). 
 (Garlet et al. 2003) reported that IL-4 is not expressed in chronic periodontal disease 
while IL-10 is expression is greater in chronic periodontitis than aggressive periodontitis. 
This increase in production does not necessarily mean that IL-10 is able to control  
periodontal progression, but it may instead slow PD through inhibition of RANKL and 
MMP (Garlet et al. 2004). Apart from direct impacts on PD, IL-10 limits macrophage and 
T cell inflammatory activity to perhaps indirectly affect disease pathogenesis (Mauri et 
al. 2003). A broadened screen of anti-inflammatory cytokines in PD tested for the 
presence of CD4+CD25+ regulatory T cells (Tregs), a known source of IL-10, in 
periodontal disease compared to gingivitis samples. Foxp3, a signature transcription 
factor for IL-10 producing Tregs, was increased in PD, as was expression of IL-10 and 
TGF-β (Nakajima et al. 2005), although Tregs were not definitively shown as the source 
of these cytokines.   Other sources of IL-10 include M2-like macrophages in adipose 
tissue (Shaul et al. 2010), and B cells that produce IL-10 in lean subjects. Our lab 
research has shown lack of actual IL-10 production by B cells in T2D subjects 
(Jagannathan et al. 2010). 
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IFNγ 
Studies showed that periodontitis is dominated by IFNγ mRNA expressed by gingival 
tissue-associated cells such as NK cells, Th1 and CD8+ T cells (Dutzan et al. 2009; Garlet 
et al. 2003; Honda et al. 2006). IFNγ activates M1 pro-inflammatory macrophages and 
attracts them to periodontal lesions. IFNγ also induces antigen presenting cells to display 
more MHC I and MHC II, thus stimulating CD8+ CD4+ T cells, respectively, to secrete 
more cytokines (Winer et al. 2009). Finally IFNγ down-regulates anti-inflammatory 
functions of Th2 T cells. IFNγ, when combined with IL-2 (see below), promotes 
maturation of naïve T cytotoxic CD8+ cells into memory and effector cells upon antigen 
recognition. 
 
 
IL-2 
IL-2 controls the differentiation and action of many cells, at least in part through an 
ability to help naïve T cell differentiate into Th1 or Th2 T cells while limiting 
differentiation to -but not function of- Th17 cells (Liao, Lin, and Leonard 2013). IL-2 
also promotes cytotoxic CD8+ T cell activity, NK cell proliferation, Treg maturation and 
action, and activation-induced cell death (AICD)- the latter of which serves to purge 
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autoimmune T cells. T cell IL-2 stimulates the Th1 immune response that is particularly 
important in periodontitis (Gemmell and Seymour 1998; Gemmell, Yamazaki, and 
Seymour 2007). In PD GCF of adult patients with chronic periodontitis and early-onset 
periodontitis contained high concentrations of IFNγ, which along with predominance of 
IL-1β and IL-2 reflect a Th1 environment in these lesions (Salvi, Beck, and Offenbacher 
1998). 
 
Section four: Immunological events in the development of periodontitis 
Gingival tissue inflammation, or “gingivitis”, is the earliest precursor of periodontal 
disease. During this phase, the gingival capillaries dilate and increase vascular 
permeability in response to accumulation of dental plaque. This hyper-permeability 
allows massive infiltration of leukocytes and the start of an acute immune response 
orchestrated by innate immune cells.  
 
After 3 days of plaque accumulation bacterial antigen is first recognized by a class of 
innate immune receptors, TLR, expressed on resident macrophages and dendritic cells 
and other antigen presenting cells. At this point the local reaction results in increased 
release of cytokines, chemokines and prostaglandins, i.e. inflammation. At the same time 
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these antigen presenting cells migrate to neighboring lymph nodes to activate adaptive 
immunity. The inflammatory response in PD is similar to the generally accepted 
paradigm for immune responses to pathogens. Neutrophils are the first line of innate 
immunity to respond to the chemokine CXCL-8/IL-8 released by resident immune cells 
including resident macrophages, dendritic cells and other antigen presenting cells. 
Neutrophils are drawn to the tissue by the IL-8, and these innate immune cells possess 
phagocytic ability and anti-microbial effects against bacterial antigen. Thus neutrophils 
are a critical first line of defense against periodontal pathogens. Macrophages/ 
mononuclear cells are subsequently recruited to the inflammatory site to ingest the debris 
and apoptic remnants (Savill et al. 2002). Although the immune cell response to 
microbial insult begins to clear pathogens, the true pathogenesis in PD occurs when the 
body fails to clear the aftermath of neutrophil/macrophage infiltration, and the lesion 
becomes chronic. 
 
 
Cells of the so-called “adaptive” immune system, B cells and T cells, play roles in the 
chronic stage of periodontal disease following unsuccessful pathogen clearance by 
neutrophils, macrophages and dendritic cells. These cells are denoted “adaptive” because 
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the population of cells “adjusts” its highly specific antigen binding molecule (B cell or T 
cell receptor, respectively) by differential outgrowth of clones with the best response to 
the pathogen of interests. These highly specific antigen-containing cells also form a 
memory pool for rapid, specific responses to secondary challenges with particular 
antigens. B cells, like macrophages and dendritic cells, serve as APCs that express MHC 
II, that forms a peptide antigen-binding crypt that, together with antigen, activates CD4+ 
T cells that have receptors that specifically recognize a given MHCII/peptide 
combination. A common belief in the field is that B cells are predominant in periodontal 
disease and play a major role in lesion progression (Berglundh, Donati, and Zitzmann 
2007), although rigorous testing of this hypothesis remains a future direction of the field. 
Weaknesses of this hypothesis include that in the acute form of PD, the antibodies 
produced by B cells are of weak avidity and are non-protective against bacteria, while 
later in chronic periodontitis the antibodies have higher avidity and are more efficient in 
clearing bacteria. Although the evidence for B cells as dominant activators of PD remains 
controversial, (Wilton, Hurst, and Sterne 1993) showed that serum antibodies in patients 
with previous periodontal disease have elevated opsonic activity for Porphyromonas 
gingivalis. 
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The second major adaptive immune cell subsets, CD4+ and CD8+ T cells, play roles in 
periodontitis that are majorly debate in the field, especially with respect to CD4+ T helper 
subtypes: Th1, Th2, Th17s and others. In general IFNγ and IL-2 polarize naïve T cell to 
Th1, while Th2 differentiation is induced by IL-4, IL-5 as mentioned above (Mosmann 
and Coffman 1989). In 2007 two major reviews supported opposite point of views as to 
roles of different CD4+ T cell subsets in PD. Houri-Haddad and co-authors (2007) 
presented the concept that Th1s are non-protective in periodontal lesions, while 
(Gemmell, Yamazaki, and Seymour 2007) presented an argument to the opposite effect: 
Th1 are protective and that Th2 s are the dominant cell in an active lesion.  This 
controversy remains unresolved at present. Regardless, T cells infiltrate periodontal 
lesions after neutrophil, then macrophage infiltration, i.e. 4-8 days after plaque 
accumulation. This finding was confirmed by IHC in experimental gingivitis (Seymour et 
al. 1988), and resembles a classical delayed hypersensitivity reaction. An extension of the 
idea that T cells are important in PD was offered by Houri et al., who concluded that due 
to the similarities in pattern -between delayed hypersensitivity reaction and periodontal 
disease- Th1 is the predominant cell type in PD lesions. Other studies reported 
dominance of both Th1 and Th2 cells (Prabhu, Michalowicz, and Mathur 1996; 
Berglundh et al. 2002). Houri concluded that Th1 transition to Th2 may be protective 
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because of the ability of Th2 cells to stimulate B cell production of antibodies against 
bacteria. Treatment protocols transferring Th2 cells to the lesion directly, or secondarily 
promoting a resolving environment by directly introducing Th2 cytokines (IL-4, IL-5, IL-
13) into the lesion should be pursued. On the other hand Gemmel et al. (2007) support the 
hypothesis that Th2 is the cause of a B cell dominated lesion. Overall, resolution of the 
many controversies regarding roles for adaptive immune system cells in PD will require 
significant additional research to reach a unified theory of roles for these cells in disease 
pathogenesis. (Houri-Haddad, Wilensky, and Shapira 2007; Gemmell, Yamazaki, and 
Seymour 2007) 
 
Section Five: Type 2 diabetes and periodontitis 
Periodontal bone loss happens largely because of losses in the balance in the Receptor 
activator of nuclear factor kappa-B (RANK)/ Receptor activator of nuclear factor kappa-
B ligand (RANK)/ Osteoprotegrin (OPG) production by cells (Duarte et al. 2007). 
RANKL and OPG play direct roles in osteoclast activation and survival (Anderson et al. 
1997; Hsu et al. 1999). RANK, the receptor for RANKL, is made by osteoclasts and 
fibroblasts in periodontal ligament (Liu, Lerner, and Teng 2010) while RANKL, the 
protein that binds RANK to activate osteoclasts, is secreted by osteoblasts, fibroblasts, B 
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cells, T cells and macrophages (Mahamed et al. 2005; Kawai et al. 2006; Belibasakis, 
Reddi, and Bostanci 2011; Onal et al. 2012). Normally osteoprotegrin (OPG), a 
decoy/soluble receptor that captures RANKL before it can bind RANK, maintains bone 
remodeling for no net loss or gain of bone mass. However, inflammation provided by 
cytokines such as TNFα, IL-1β and others detailed above results in a loss of balance and 
bone remodeling that favors more osteoclastic resorption. Just as RANKL expression 
increases due to changes in the micro-environment in the periodontal tissues, RANKL 
expression increases in obesity-associated T2D (Cao, Sun, and Gao). Poorly-controlled 
diabetes is further associated with an increased RANKL:OPG ratio in GCF (Santos et al. 
2010).  
 
Leukocytes that circulate through periodontal tissue behave differently in cases of 
chronic inflammatory disease, which may explain the link between PD and systemic 
diseases like T2D. For example, inflammatory lymphocytes in adipose tissue, which 
causes insulin resistance and, ultimately obesity-associated T2D recirculate throughout 
the body, including likely recirculation through the richly vascularized gingiva. It is 
therefore important to briefly discuss the changes in immune cells associated with obesity 
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and T2D, dubbed “immunometabolism” in the next chapter to highlight altered 
leukocytes behavior that may predispose PD in individuals with inflamed adipose tissue. 
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Section Six: Effect of adipose tissue on immune response 
Immune cells invade the adipose tissue to cause adipose inflammation under certain 
circumstances like high fat intake, increased free fatty acids and chronic activation due to 
co-morbid inflammatory diseases. Neutrophils are the first cells to invade the inflamed 
adipose tissue of high fat fed C57BL/6J mice. When these neutrophils were isolated from 
mice and activated with PMA and/or IL-8 at day 3-7 they adhered more to adipocytes 
compared to those taken at day 0 (Elgazar-Carmon et al. 2008). B cells and T cells invade 
next followed by macrophages before insulin resistance occurs (Duffaut et al. 2009). 
Although this order of cellular infiltration into the expanding adipose tissue remains 
unresolved, one important speculation about this phenomenon is that lymphocytes prime 
the adipose tissue to receive the macrophages. 
 
 
Monocytes and their differentiated cousins, macrophages, play a major role in inflamed 
adipose tissue in both mice and in humans. Macrophages infiltrate the adipose tissue 
aggressively in response to high fat diet (Apovian et al. 2008; Strissel et al. 2007), and 
produce their main pro-inflammatory effects via JNK (Solinas et al. 2007). Maximum 
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cytokine release and adipocyte death was seen with maximum monocyte infiltration 
(Strissel et al. 2007), indicating a close relationship between macrophage function and 
adipose tissue health.   Similarly, monocytes produce more IL-1β, TNFα and IL-6 when 
isolated from peripheral blood of T2D human subjects (Giulietti et al. 2004) compared to 
non-T2Ds.  This inflammation induces the peripheral monocytes to secrete more 
cytokines (Dasu et al. 2010) by the effect of elevated TLR4 ligands known to trigger 
cytokine production.  A feed-forward loop between adipose tissue and macrophages 
occurs in which activated macrophages will activate adipocytes by TNFα production 
perpetuating both local and systemic inflammation. Finally, adipocytes secrete FFA 
which further activate monocytes (Suganami, Nishida, and Ogawa 2005; Randle et al. 
1963).  
 
Macrophages can be simplistically sub-classified into M1 and M2 subsets. M1 is 
“classically” activated by IFNγ and LPS while M2 is “alternatively” activated by IL-4 
and IL-13. M1 is thereby pro-inflammatory and phagocytic while M2s are anti-
inflammatory and helps in tissue repair (Wynn, Chawla, and Pollard 2013). M1s are 
thought to be the dominant macrophage phenotype in obesity-associated insulin 
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resistance, but at a certain point the remodeling of adipose occurs and M2 phenotype 
takes over significantly reducing adipocytes size (Strissel et al. 2007). 
 
It is debatable whether B cells and T cells are protective in obesity, or are part of a 
pathogenic process. The sustained endotoxemia in T2D, in which toxins keep activating 
the immune response (Creely et al. 2007) may activate not only innate immune cells as 
indicated above, but also B cells, and perhaps to a lesser extent, T cells. It has been 
shown that B cells are hyper-stimulated in T2D by TLR4 receptors (DeFuria et al. 2013). 
The importance of B cells in T2D is indicated by studies in high-fat diet fed B cell-null 
mice, which developed less insulin resistance than wild type mice despite equal obesity. 
Thus the combination of endotoxemia plus up-regulation of TLR receptor suggest that B 
cells promote obesity associated metabolic syndrome (Ip, Hogan, and Nikolajczyk 2015). 
On the other hand adipose tissue secretes more B cell activating factor (BAFF) in ob/ob 
mice (Kim et al. 2009) in response to  TLR challenged (Yan et al. 2014) and increase 
oxidative stress (Tada et al. 2013). 
 
T cells similarly pay important roles in obesity/T2D-associated inflammation that may 
impact periodontal health. CD8+ T cytotoxic cells infiltrate the expanding adipose tissue 
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in high fat fed mice prior to macrophages (Nishimura et al. 2009). This group also 
showed that CD8+ T cells facilitate macrophage infiltration by initiating an inflammatory 
cascade.  
 
One subset of CD4+ T cells, the Th17 subset, deserve special mention in the context of 
T2D, and thus perhaps T2D-associated PD. Th17 cells have been linked to multiple 
inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and psoriasis (Pene 
et al. 2008; Jagannathan-Bogdan et al. 2011; Zuniga et al. 2010). Th17s produce IL-17, 
IL-21, IL-22 and mip-3 which induce inflammation by activation of IL-17 receptor (IL-
17R) among others (Onishi and Gaffen 2010). In serum, Th17 cytokines are directly 
related to increased %HbA1c and are elevated in obese T2D compared to lean or obese 
metabolically healthy individuals (Jagannathan-Bogdan et al. 2011). In adipose tissue 
Th17s may accelerate lipolysis and insulin resistance thus increasing free fatty acid and 
glucose formation (Shin, Shin, and Noh 2009). 
 
Our knowledge about the immunological sequence of periodontal disease pathogenesis is 
derived primarily from analysis of peripheral blood immune cells (Karima 2005; Omori 
2008; Van Dyke 1981; Salvi 1997; Graves 2004; M. Jagannathan 2009, 2010, 2011). 
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However lack of technology that allows accurate functional analysis of local immune 
cells residing in the periodontal tissues impedes further understanding of the biology of 
the disease, especially given the complexities introduced by the complex relationships 
amongst PD, the various immune cells subsets, and T2D as outlined above. The overall 
purpose of this study therefore is to analyze gingival immune cells on a single cell level 
and provide a preliminary comparison of cells harvested from tissues from subjects with 
periodontal disease but systemically healthy, periodontal disease patients diagnosed with 
type 2 diabetes, and T2D subjects with no periodontal disease. 
 
  
		 29	
Materials and Methods 
Patient selection 
Patients seeking dental treatment in Boston University Henry M. Goldman School of 
Dental Medicine, Departments of Periodontics and General Dentistry were screened 
using the dental appointment software Salud (Two-Ten Health Ltd, Dublin). Exclusion 
criteria included patients who had infections other than PD, antibiotic use, smokers, drug 
and alcohol abuse and use of steroids. Relatively healthy gingival tissues were removed 
during standard-of-care surgery for crown lengthening, or diseased gingival tissues from 
subjects with chronic periodontitis with or without T2D removed in standard of care 
procedures. Chronic periodontitis was diagnosed according to Armitage 1999 criteria. 
The 3 groups were BMI matched to exclude any confounding effect of obesity induced 
inflammation. 
 
Gingival sample collection 
Patients consented to participate in the study on the day of the surgery. Excised tissues 
were collected immediately into a 15ml conical tube containing cold RPMI Medium 1640 
(Gibco Life Techonologies) with 10% Fetal Bovine Serum (Atlanta biological, Norcross, 
GA) and 1% Penicillin-Streptomycin (Thermofisher, Waltham, MA) and kept on ice in a 
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Styrofoam cooler. Samples were vigorously washed to remove excess external blood then 
weighed on an analytical balance. Samples were sliced with a sterile sharp razor in a petri 
dish and incubated in a shaker with Worthington Collagenase I (LS004196), 1 mg/ml, in 
Medium 199 (Gibco #11043-023) / BSA 1% (molecular grade).  Collagenase stock was 
prepared in bulk and frozen in 10 ml aliquots. Leftovers of this stock were discarded after 
a single thaw. Samples were incubated in a bacterial shaker/thermostat at ~220 rpm 
and 37°C for 60 min. The collagenase-released cells were then filtered through 70µm 
filter and mashed using a sterile syringe plunger. RPMI was added and the mix was 
centrifuged at 1300 RPM for 10 minutes. Samples were washed with Dulbecco’s 
Phosphate-Buffered Saline (Corning incorporated) in Eppendorf tubes at 2200 RPM for 6 
minutes. Afterwards the sample was incubated with Zombie Aqua (Fixable viability Kit, 
Biolegend) for 25 minutes followed by a PBS wash. The cell suspension was then 
incubated with a 10-color flow cytometry panel developed by Boston University Flow 
Core facility for 25 minutes. Cells were sorted into CD4+ T helper cells, CD8+ T cytotoxic 
cells, CD11b+ myeloid cells (monocytes/macrophages) and CD19+ B cells. The sorted 
cells were then activated by population-specific stimulations for 36-40 hours and 
transferred to 96-well plate for ELISpot assay. CD4+ cells and CD8+ cells were 
stimulated by phorbol 12-myristate 13-acetate (Abcam) and Ionomycin (Abcam). 
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Enzyme-linked ImmunoSpot (ELISpot) assay 
96 well plates were plated with a capture antibody specific for either IL-2, IL-4, IL-6, IL-
8, IL-10, IL-13, IL-17a, TNFα, IFNγ, Mip3 or Granzyme then incubated for 5-6 hours at 
room temperature. Plates were washed two times with PBS and two times with RPMI, 
then left 15 minutes in the incubator with 50µl RPMI per well before adding the sorted 
cells described above.  After 36-40 hours the plates were washed with PBS then with 
PBST (Tween 0.1%) 2x, to remove cells. Detection-biotinylated antibodies were added at 
a final dilution shown in and incubated overnight at 4o C. The plates were then washed 
with PBST and incubated with streptavidin conjugated Alkaline Phosphatase at a final 
dilution of 1:1000 in PBST for one hour. Plates were then washed and soaked in PBST 
for another hour. Last, 100µl/well of Vector Blue substrate mix was added and plates 
were kept in dark room until spots were macroscopically detectible. Spots were counted 
under a dissecting microscope to calculate percentage of cytokine-producing cells using 
the formula: 
 #spots / # of cells plated. 
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Statistical analysis 
Statistical significance in percentage of cells producing cytokines was calculated by one-
way ANOVA among the three groups. 
 
Gating strategy: 
After labeling with the flow panel in Table 1, the cell samples were analyzed and sorted 
in a FACS Aria in the BUSM Flow Core. The cells were gated for live cells after 
excluding possible RBCs and debris on the side scatter and forward scatter axes. The live 
cells were then further purified to immune cells population on the CD45+. Further 
purification of the sample was done to sort into CD3+CD4+ T helper cells, CD3+CD8+ 
cytotoxic T cells, CD19+CD20+CD3- B cells and CD11b+ myeloid lineage cells.  
 
 
Cell Subset distribution: 
The frequencies of cell sub-types in the tissues relative to total CD45+ cells was 
calculated using Flowjo analysis and the gating strategy in Fig 1. A statistical formula 
was set to calculate the percentage of CD4+, CD8+, CD11b+, CD19+ and CD56+ cells 
from the parental CD45+ live cell population. 
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Ab	 Final	Conc.	 Amount	added	to	1mL	PBS	 Company	 Product	Number	
IL-2	 1:60	 17	ul	 R&D	 SEL202	
IL-4	 15	ug/ml	 15	ul	 MABTECH	 3410-3-1000 
IL-6	 15	ug/ml	 15	ul	 MABTECH	 3460-3-1000 
IL-8	 1:60	 17	ul	 R&D	 SEL208	
IL-10	 1:60	 17	ul	 R&D	 SEL217B	
IL-13	 1:60	 17	ul	 R&D	 SEL213	
IL-17A	 5	ug/ml	 20	ul	 eBioscience	 14-7178-85	
TNFα	 1:60	 17	ul	 R&D	 SEL210	
IFNgγ	 15	ug/ml	 15	ul	 MABTECH	 3420-3-1000 
Gran.	B	 1:60	 17	ul	 R&D	 SEL2906	
 
Table 1. Enzyme linked immunospot (ELIspot) capturing antibody final concentrations, 
amount added to 1ml PBSTB, Company and product number 
 
Ab	 Final	Conc.	 Amount	added	to	1mL	PBSTB	 Company	 Product	Number	
IL-2	 1:60	 17	ul	 R&D	 SEL202	
IL-4	 1ug/ml	 1	ul	 MABTECH	 3410-6-250	
IL-6	 1ug/ml	 1	ul	 MABTECH	 3460-6-250	
IL-8	 1:60	 17	ul	 R&D	 SEL208	
IL-10	 1:60	 17	ul	 R&D	 SEL217B	
IL-13	 1:60	 17	ul	 R&D	 SEL213	
IL-17A	 4ug/ml	 4	ul	 eBioscience	 13-7179-81	
TNFα	 1:60	 17	ul	 R&D	 SEL210	
IFNγ	 1ug/ml	 1	ul	 MABTECH	 3420-6-250	
Gran.	B	 1:60	 17	ul	 R&D	 SEL2906	
 
Table 2. Enzyme linked immunospot (ELIspot) detection antibodies final concentrations, 
amount added to 1ml PBSTB, Company and product number. 	  
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Zombie Aqua 1:200 1uL 
CD4 APC 1:200 1 ul 
CD8 Percp 5.5 1:400 0.5uL 
CD45 APC 1:200 1 uL 
CD3 APC-Cy7 1:200 1 uL 
CD11b PE-7 1:200 1 uL 
CD45 PacB 1:200 1 uL 
CD20 FITC 1:200 1 uL 
RANKL PE 1:100 2uL 
CD19 BUV395 1:100 2uL 
CD56 Alexa700 1:100 2uL 
 
Table 3. Flow cytometry antibody concentrations and amount added to 200ul of PBS 
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Figure	1	shows	flowcytometry	gating	strategy	
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Results 
Subset cell frequencies 
All gingival immune cell subsets analyzed had similar frequencies in tissues from 
healthy, periodontitis and periodontitis/type 2 diabetes subjects. CD4+ T cells (26-31%) 
were the most dominant cell type in the gingival cell preparations from all subjects. CD8+ 
T cells were the second most frequent cell type (18.5-22.5%), followed by CD11b+ 
myeloid cells (monocytes/macrophages; 12%), CD19+ B cells (5-7.5%), and CD56+ 
natural killer (NK) cells (2-3%) (Fig. 2).  
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Fig.	2	shows	the	immune	cell	subtype	frequencies	out	of	total	CD45+.	
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Gingival immune cells associated patterns of cytokines 
A higher frequency of CD4+ T helper cells from T2D subjects produce a select 
number of cytokines  
Fig. 3 shows the frequency of cytokine producing CD4+ T cells in samples from the three 
groups of subjects, the frequency of CD4+ cells that secrete IL-2 was minimal in the 
healthy group (H; then you use H for healthy for the rest)(mean=1.3%) while samples 
from PD alone or PD with T2D had mean percentages of CD4+ cells of 3.59% and 
8.63%, respectively (P<0.05). CD4+ IL-10 secreting cells were similarly frequent in 
samples from the healthy and periodontitis groups (0.3% and 0.16% respectively) 
whereas samples from T2D subjects with PD had a higher frequency of IL-10+ cells 
(1.2%; P<0.0001). TNFα was produced by a similar proportion of cells from the H and 
PD groups at 1.9% and 2.7%, respectively, but the T2D samples had almost 3 fold the 
frequency of CD4+ TNFα+ cells (7%; P<0.001). IFNγ-producing cells were least frequent 
in H (4.4%), and PD  (4.15%) samples and higher in T2D samples (10%; P<0.01). The 
assay showed few (if any) CD4+ T cells produced IL-4, IL-6, IL-8, IL-13, IL-17a, or 
Granzyme B under these conditions. Mip3-producing CD4+ cells were similarly frequent 
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in H and P samples (1.4% and 1.8% respectively), while the T2D samples showed a 
statistically higher frequency of Mip-3 producing cells 3.7% (P<0.05). The percentage of 
CD4+ producing IL-2, IL-10, TNFα and IFNγ cells in T2D group are statistically 
different compared to H and P cells. 
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Figure	3	shows	the	percentage	of	CD4+	cytokine-producing	cells		
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No Differences in frequency of CD8+ cytotoxic T cells producing cytokines amongst 
the three groups 
The EILSPOT assay showed spots (i.e. a positive signal) in wells testing for CD8+ cells 
that produced IL-2, TNFα, IFNγ and Granzyme B, but results amongst subject samples 
were statistical similar (Fig 4). IL-2- producing CD8+ cells ranged from 4.5-7.7%, TNFα, 
6.1-9.5%, IFNγ ,12.3 and 17.9% with trend towards higher number of cell producing 
IFNγ in cells from healthy population (p=0.4). The ELISPOT showed few if any CD8+ 
cells secreted IL-4, IL-6, IL-8, IL-13, IL-17 and Mip3. We conclude CD8+ cell cytokine 
production does not associate with disease status. 
Figure	4	shows	the	percentage	of	CD8+cytokine-producing	cells	
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Discussion 
We isolated immune cells from gingival tissues and obtained functional 
information on a single cell level for the first time. We collected tissues from 3 
types of subjects: 1- systemically and periodontally healthy (H); 2- systemically 
healthy and diagnosed with chronic periodontitis (PD); and 3- systemically 
diagnosed with type 2 diabetes and chronic periodontitis (T2D). Chronic 
periodontitis was diagnosed according to Armitage 1999 criteria. The 3 groups 
were BMI matched to exclude any confounding effect of obesity induced 
inflammation. 
 
One limitation of our work is that there were no samples from patients with T2D 
and no periodontal disease due to the scarcity of this cohort in our clinic. Also, 
the number of samples from the (H) and (T2D) is currently being increased. 
Numerous samples were been sacrificed in the development of this new 
technique. Overall, the results shown are preliminary pending more subjects 
recruitment of more subjects.  
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One of the clinical caveats of our study is that we measured the proportion of 
gingival immune cells that secrete pro- or anti-inflammatory cytokines in samples 
from PD and T2D with confounding PD after phase I (scaling and root planning) 
treatment.  In contrast, H samples were collected from subjects undergoing 
crown lengthening procedures, i.e. absent phase I treatment. The demonstration 
that immune cells from subjects with T2D-associated PD have the highest 
proportion of cytokine-producing cells, taken together with numerous 
demonstrations that obesity and T2D promote pro-inflammatory T cell function 
(Verwaerde et al. 2006; Feuerer et al. 2009; Nishimura et al. 2009; Jagannathan-
Bogdan et al. 2011; Yang et al. 2010) provides the first cellular explanation for 
the increased aggressiveness of PD in T2D. Our findings proposed that B cell 
frequency was lower than T cells (% vs %) contradicts the classical 
understanding of periodontal disease shown by IHC studies (Schroeder 1960s). 
This finding may be attributed to the condition of the collected tissues that may 
have differed from that of Schroeder, or because our T2D patients had 
undergone phase I therapy prior to the surgical intervention. This finding may be 
explained as a phase of incomplete resolution of periodontal inflammation as the 
bacterial load decreased but not to the extent of complete resolution of the lesion 
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marked by persistent deep pockets, and may explain why lesions relapse more 
frequently and quickly in T2D/PD compared to PD/systemically healthy subjects. 
 
We measured the phenotype of these gingival cells using the novel functional 
analysis method described above on a single cell level. Using PMA/Ionomycin 
somewhat mimics bacterial challenge, but high proportion of pro-inflammatory 
cells (Th1) cells marked by production of IL-2 and IFNγ production further 
emphasize that T2D primes T cells for increased inflammatory cytokine 
production in cells that populate periodontal tissue. This result supports the 
findings by Houri (2007)  that Th1cell dominate the periodontally active lesion 
while it contradicts the research by Gemmell et al (2007). The latter opinion is 
highly debatable in the field of immunology as our understanding of (Th1) cells is 
pro-inflammatory in nature.  
 
Functional analysis of T helper cells revealed a more pro-inflammatory profile in 
(T2D) group upon stimulation. IL-2, TNFα, IFNγ and trend towards higher with IL-
2. Together with the elevated amount cells per gram; We explain this 
phenomenon can be consideredas a period of “transient gingivitis” where in 
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which the inflammation is partially resolved by the scaling and root planing. 
However if the bacterial virulence is not fully resolved by the clinician the 
inflammation will reoccur with signs of periodontal damage. This finding has been 
confirmed by (Tervonen 1997) who found that diabetic patients with poor glucose 
control show short term improvement of periodontal health, but have more rapid 
recurrence of deep pockets. Future studies are needed to assess function of B 
cells and macrophages, and to thereby create a comprehensive immunological 
map of health, PD and T2D-associated PD and thereby identify dominant cells 
that may be neutralized to prevent disease remission after standard phase I 
treatment. 
  
		 46	
 
 
  
		 47	
References Acosta-Rodriguez,	E.	V.,	G.	Napolitani,	A.	Lanzavecchia,	and	F.	Sallusto.	2007.	'Interleukins	1beta	and	6	but	not	transforming	growth	factor-beta	are	essential	for	the	differentiation	of	interleukin	17-producing	human	T	helper	cells',	Nature	immunology,	8:	942-9.	ADA.	2015.	'(2)	Classification	and	diagnosis	of	diabetes',	Diabetes	care,	38	Suppl:	S8-S16.	Anderson,	D.	M.,	E.	Maraskovsky,	W.	L.	Billingsley,	W.	C.	Dougall,	M.	E.	Tometsko,	E.	R.	Roux,	M.	C.	Teepe,	R.	F.	DuBose,	D.	Cosman,	and	L.	Galibert.	1997.	'A	homologue	of	the	TNF	receptor	and	its	ligand	enhance	T-cell	growth	and	dendritic-cell	function',	Nature,	390:	175-9.	Apovian,	C.	M.,	S.	Bigornia,	M.	Mott,	M.	R.	Meyers,	J.	Ulloor,	M.	Gagua,	M.	McDonnell,	D.	Hess,	L.	Joseph,	and	N.	Gokce.	2008.	'Adipose	macrophage	infiltration	is	associated	with	insulin	resistance	and	vascular	endothelial	dysfunction	in	obese	subjects',	Arteriosclerosis,	thrombosis,	and	vascular	biology,	28:	1654-9.	Bandyopadhyay,	D.,	N.	M.	Marlow,	J.	K.	Fernandes,	and	R.	S.	Leite.	2010.	'Periodontal	disease	progression	and	glycaemic	control	among	Gullah	African	Americans	with	type-2	diabetes',	Journal	of	clinical	periodontology,	37:	501-9.	Belibasakis,	G.	N.,	D.	Reddi,	and	N.	Bostanci.	2011.	'Porphyromonas	gingivalis	induces	RANKL	in	T-cells',	Inflammation,	34:	133-8.	Bendre,	M.	S.,	D.	C.	Montague,	T.	Peery,	N.	S.	Akel,	D.	Gaddy,	and	L.	J.	Suva.	2003.	'Interleukin-8	stimulation	of	osteoclastogenesis	and	bone	resorption	is	a	mechanism	for	the	increased	osteolysis	of	metastatic	bone	disease',	Bone,	33:	28-37.	Benguigui,	C.,	V.	Bongard,	J.	B.	Ruidavets,	B.	Chamontin,	M.	Sixou,	J.	Ferrieres,	and	J.	Amar.	2010.	'Metabolic	syndrome,	insulin	resistance,	and	periodontitis:	a	cross-sectional	study	in	a	middle-aged	French	population',	Journal	of	clinical	
periodontology,	37:	601-8.	Berglundh,	T.,	M.	Donati,	and	N.	Zitzmann.	2007.	'B	cells	in	periodontitis:	friends	or	enemies?',	Periodontology	2000,	45:	51-66.	Berglundh,	T.,	B.	Liljenberg,	A.	Tarkowski,	and	J.	Lindhe.	2002.	'The	presence	of	local	and	circulating	autoreactive	B	cells	in	patients	with	advanced	periodontitis',	
Journal	of	clinical	periodontology,	29:	281-6.	Campus,	G.,	A.	Salem,	S.	Uzzau,	E.	Baldoni,	and	G.	Tonolo.	2005.	'Diabetes	and	periodontal	disease:	a	case-control	study',	Journal	of	periodontology,	76:	418-25.	Cao,	J.	J.,	L.	Sun,	and	H.	Gao.	2010.	'Diet-induced	obesity	alters	bone	remodeling	leading	to	decreased	femoral	trabecular	bone	mass	in	mice',	Annals	of	the	
New	York	Academy	of	Sciences,	1192:	292-7.	Chaffee,	B.	W.,	and	S.	J.	Weston.	2010.	'Association	between	chronic	periodontal	disease	and	obesity:	a	systematic	review	and	meta-analysis',	Journal	of	
periodontology,	81:	1708-24.	
		 48	
Cohen,	D.	W.,	L.	A.	Friedman,	J.	Shapiro,	G.	C.	Kyle,	and	S.	Franklin.	1970.	'Diabetes	mellitus	and	periodontal	disease:	two-year	longitudinal	observations.	I',	
Journal	of	periodontology,	41:	709-12.	Creely,	S.	J.,	P.	G.	McTernan,	C.	M.	Kusminski,	M.	Fisher	f,	N.	F.	Da	Silva,	M.	Khanolkar,	M.	Evans,	A.	L.	Harte,	and	S.	Kumar.	2007.	'Lipopolysaccharide	activates	an	innate	immune	system	response	in	human	adipose	tissue	in	obesity	and	type	2	diabetes',	American	journal	of	physiology.	Endocrinology	and	metabolism,	292:	E740-7.	Cutler,	C.	W.,	E.	A.	Shinedling,	M.	Nunn,	R.	Jotwani,	B.	O.	Kim,	S.	Nares,	and	A.	M.	Iacopino.	1999.	'Association	between	periodontitis	and	hyperlipidemia:	cause	or	effect?',	Journal	of	periodontology,	70:	1429-34.	Dasu,	M.	R.,	S.	Devaraj,	S.	Park,	and	I.	Jialal.	2010.	'Increased	toll-like	receptor	(TLR)	activation	and	TLR	ligands	in	recently	diagnosed	type	2	diabetic	subjects',	
Diabetes	care,	33:	861-8.	DeFuria,	J.,	A.	C.	Belkina,	M.	Jagannathan-Bogdan,	J.	Snyder-Cappione,	J.	D.	Carr,	Y.	R.	Nersesova,	D.	Markham,	K.	J.	Strissel,	A.	A.	Watkins,	M.	Zhu,	J.	Allen,	J.	Bouchard,	G.	Toraldo,	R.	Jasuja,	M.	S.	Obin,	M.	E.	McDonnell,	C.	Apovian,	G.	V.	Denis,	and	B.	S.	Nikolajczyk.	2013.	'B	cells	promote	inflammation	in	obesity	and	type	2	diabetes	through	regulation	of	T-cell	function	and	an	inflammatory	cytokine	profile',	Proceedings	of	the	National	Academy	of	
Sciences	of	the	United	States	of	America,	110:	5133-8.	Denis,	G.	V.,	and	M.	S.	Obin.	2013.	''Metabolically	healthy	obesity':	origins	and	implications',	Molecular	aspects	of	medicine,	34:	59-70.	Duarte,	P.	M.,	J.	B.	Neto,	M.	Z.	Casati,	E.	A.	Sallum,	and	F.	H.	Nociti,	Jr.	2007.	'Diabetes	modulates	gene	expression	in	the	gingival	tissues	of	patients	with	chronic	periodontitis',	Oral	diseases,	13:	594-9.	Duffaut,	C.,	J.	Galitzky,	M.	Lafontan,	and	A.	Bouloumie.	2009.	'Unexpected	trafficking	of	immune	cells	within	the	adipose	tissue	during	the	onset	of	obesity',	
Biochemical	and	biophysical	research	communications,	384:	482-5.	Dutzan,	N.,	R.	Vernal,	M.	Hernandez,	A.	Dezerega,	O.	Rivera,	N.	Silva,	J.	C.	Aguillon,	J.	Puente,	P.	Pozo,	and	J.	Gamonal.	2009.	'Levels	of	interferon-gamma	and	transcription	factor	T-bet	in	progressive	periodontal	lesions	in	patients	with	chronic	periodontitis',	Journal	of	periodontology,	80:	290-6.	Elgazar-Carmon,	V.,	A.	Rudich,	N.	Hadad,	and	R.	Levy.	2008.	'Neutrophils	transiently	infiltrate	intra-abdominal	fat	early	in	the	course	of	high-fat	feeding',	Journal	
of	lipid	research,	49:	1894-903.	Engebretson,	S.	P.,	L.	G.	Hyman,	B.	S.	Michalowicz,	E.	R.	Schoenfeld,	M.	C.	Gelato,	W.	Hou,	E.	R.	Seaquist,	M.	S.	Reddy,	C.	E.	Lewis,	T.	W.	Oates,	D.	Tripathy,	J.	A.	Katancik,	P.	R.	Orlander,	D.	W.	Paquette,	N.	Q.	Hanson,	and	M.	Y.	Tsai.	2013.	'The	effect	of	nonsurgical	periodontal	therapy	on	hemoglobin	A1c	levels	in	persons	with	type	2	diabetes	and	chronic	periodontitis:	a	randomized	clinical	trial',	Jama,	310:	2523-32.	
		 49	
Essner,	R.,	K.	Rhoades,	W.	H.	McBride,	D.	L.	Morton,	and	J.	S.	Economou.	1989.	'IL-4	down-regulates	IL-1	and	TNF	gene	expression	in	human	monocytes',	Journal	
of	immunology,	142:	3857-61.	Fabbrini,	E.,	M.	Cella,	S.	A.	McCartney,	A.	Fuchs,	N.	A.	Abumrad,	T.	A.	Pietka,	Z.	Chen,	B.	N.	Finck,	D.	H.	Han,	F.	Magkos,	C.	Conte,	D.	Bradley,	G.	Fraterrigo,	J.	C.	Eagon,	B.	W.	Patterson,	M.	Colonna,	and	S.	Klein.	2013.	'Association	between	specific	adipose	tissue	CD4+	T-cell	populations	and	insulin	resistance	in	obese	individuals',	Gastroenterology,	145:	366-74	e1-3.	Faria-Almeida,	R.,	A.	Navarro,	and	A.	Bascones.	2006.	'Clinical	and	metabolic	changes	after	conventional	treatment	of	type	2	diabetic	patients	with	chronic	periodontitis',	Journal	of	periodontology,	77:	591-8.	Feuerer,	M.,	L.	Herrero,	D.	Cipolletta,	A.	Naaz,	J.	Wong,	A.	Nayer,	J.	Lee,	A.	B.	Goldfine,	C.	Benoist,	S.	Shoelson,	and	D.	Mathis.	2009.	'Lean,	but	not	obese,	fat	is	enriched	for	a	unique	population	of	regulatory	T	cells	that	affect	metabolic	parameters',	Nat	Med,	15:	930-9.	Gallagher,	E.	J.,	D.	Leroith,	and	E.	Karnieli.	2011.	'The	metabolic	syndrome--from	insulin	resistance	to	obesity	and	diabetes',	The	Medical	clinics	of	North	
America,	95:	855-73.	Garlet,	G.	P.,	W.	Martins,	Jr.,	B.	R.	Ferreira,	C.	M.	Milanezi,	and	J.	S.	Silva.	2003.	'Patterns	of	chemokines	and	chemokine	receptors	expression	in	different	forms	of	human	periodontal	disease',	Journal	of	periodontal	research,	38:	210-7.	Garlet,	G.	P.,	W.	Martins,	Jr.,	B.	A.	Fonseca,	B.	R.	Ferreira,	and	J.	S.	Silva.	2004.	'Matrix	metalloproteinases,	their	physiological	inhibitors	and	osteoclast	factors	are	differentially	regulated	by	the	cytokine	profile	in	human	periodontal	disease',	
Journal	of	clinical	periodontology,	31:	671-9.	Geerts,	S.	O.,	M.	Nys,	M.	P.	De,	J.	Charpentier,	A.	Albert,	V.	Legrand,	and	E.	H.	Rompen.	2002.	'Systemic	release	of	endotoxins	induced	by	gentle	mastication:	association	with	periodontitis	severity',	Journal	of	periodontology,	73:	73-8.	Gemmell,	E.,	and	G.	J.	Seymour.	1998.	'Cytokine	profiles	of	cells	extracted	from	humans	with	periodontal	diseases',	Journal	of	dental	research,	77:	16-26.	Gemmell,	E.,	K.	Yamazaki,	and	G.	J.	Seymour.	2007.	'The	role	of	T	cells	in	periodontal	disease:	homeostasis	and	autoimmunity',	Periodontology	2000,	43:	14-40.	Genco,	R.	J.,	S.	G.	Grossi,	A.	Ho,	F.	Nishimura,	and	Y.	Murayama.	2005.	'A	proposed	model	linking	inflammation	to	obesity,	diabetes,	and	periodontal	infections',	
Journal	of	periodontology,	76:	2075-84.	Giulietti,	A.,	K.	Stoffels,	B.	Decallonne,	L.	Overbergh,	and	C.	Mathieu.	2004.	'Monocytic	expression	behavior	of	cytokines	in	diabetic	patients	upon	inflammatory	stimulation',	Annals	of	the	New	York	Academy	of	Sciences,	1037:	74-8.	Graves,	D.	T.,	D.	Fine,	Y.	T.	Teng,	T.	E.	Van	Dyke,	and	G.	Hajishengallis.	2008.	'The	use	of	rodent	models	to	investigate	host-bacteria	interactions	related	to	periodontal	diseases',	Journal	of	clinical	periodontology,	35:	89-105.	
		 50	
Gurav,	A.	N.	2014.	'The	association	of	periodontitis	and	metabolic	syndrome',	Dental	
research	journal,	11:	1-10.	Hajishengallis,	G.,	and	R.	J.	Lamont.	2014.	'Breaking	bad:	manipulation	of	the	host	response	by	Porphyromonas	gingivalis',	European	journal	of	immunology,	44:	328-38.	Han,	D.	H.,	S.	Lim,	D.	Paek,	and	H.	D.	Kim.	2012.	'Periodontitis	could	be	related	factors	on	metabolic	syndrome	among	Koreans:	a	case-control	study',	Journal	
of	clinical	periodontology,	39:	30-7.	Honda,	T.,	H.	Domon,	T.	Okui,	K.	Kajita,	R.	Amanuma,	and	K.	Yamazaki.	2006.	'Balance	of	inflammatory	response	in	stable	gingivitis	and	progressive	periodontitis	lesions',	Clinical	and	experimental	immunology,	144:	35-40.	Houri-Haddad,	Y.,	A.	Wilensky,	and	L.	Shapira.	2007.	'T-cell	phenotype	as	a	risk	factor	for	periodontal	disease',	Periodontol	2000,	45:	67-75.	Hsu,	H.,	D.	L.	Lacey,	C.	R.	Dunstan,	I.	Solovyev,	A.	Colombero,	E.	Timms,	H.	L.	Tan,	G.	Elliott,	M.	J.	Kelley,	I.	Sarosi,	L.	Wang,	X.	Z.	Xia,	R.	Elliott,	L.	Chiu,	T.	Black,	S.	Scully,	C.	Capparelli,	S.	Morony,	G.	Shimamoto,	M.	B.	Bass,	and	W.	J.	Boyle.	1999.	'Tumor	necrosis	factor	receptor	family	member	RANK	mediates	osteoclast	differentiation	and	activation	induced	by	osteoprotegerin	ligand',	
Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	
America,	96:	3540-5.	Human	Microbiome	Jumpstart	Reference	Strains,	Consortium,	K.	E.	Nelson,	G.	M.	Weinstock,	S.	K.	Highlander,	K.	C.	Worley,	H.	H.	Creasy,	J.	R.	Wortman,	D.	B.	Rusch,	M.	Mitreva,	E.	Sodergren,	A.	T.	Chinwalla,	M.	Feldgarden,	D.	Gevers,	B.	J.	Haas,	R.	Madupu,	D.	V.	Ward,	B.	W.	Birren,	R.	A.	Gibbs,	B.	Methe,	J.	F.	Petrosino,	R.	L.	Strausberg,	G.	G.	Sutton,	O.	R.	White,	R.	K.	Wilson,	S.	Durkin,	M.	G.	Giglio,	S.	Gujja,	C.	Howarth,	C.	D.	Kodira,	N.	Kyrpides,	T.	Mehta,	D.	M.	Muzny,	M.	Pearson,	K.	Pepin,	A.	Pati,	X.	Qin,	C.	Yandava,	Q.	Zeng,	L.	Zhang,	A.	M.	Berlin,	L.	Chen,	T.	A.	Hepburn,	J.	Johnson,	J.	McCorrison,	J.	Miller,	P.	Minx,	C.	Nusbaum,	C.	Russ,	S.	M.	Sykes,	C.	M.	Tomlinson,	S.	Young,	W.	C.	Warren,	J.	Badger,	J.	Crabtree,	V.	M.	Markowitz,	J.	Orvis,	A.	Cree,	S.	Ferriera,	L.	L.	Fulton,	R.	S.	Fulton,	M.	Gillis,	L.	D.	Hemphill,	V.	Joshi,	C.	Kovar,	M.	Torralba,	K.	A.	Wetterstrand,	A.	Abouellleil,	A.	M.	Wollam,	C.	J.	Buhay,	Y.	Ding,	S.	Dugan,	M.	G.	FitzGerald,	M.	Holder,	J.	Hostetler,	S.	W.	Clifton,	E.	Allen-Vercoe,	A.	M.	Earl,	C.	N.	Farmer,	K.	Liolios,	M.	G.	Surette,	Q.	Xu,	C.	Pohl,	K.	Wilczek-Boney,	and	D.	Zhu.	2010.	'A	catalog	of	reference	genomes	from	the	human	microbiome',	
Science,	328:	994-9.	Ide,	M.,	D.	McPartlin,	P.	Y.	Coward,	M.	Crook,	P.	Lumb,	and	R.	F.	Wilson.	2003.	'Effect	of	treatment	of	chronic	periodontitis	on	levels	of	serum	markers	of	acute-phase	inflammatory	and	vascular	responses',	Journal	of	clinical	
periodontology,	30:	334-40.	Ip,	B.	C.,	A.	E.	Hogan,	and	B.	S.	Nikolajczyk.	2015.	'Lymphocyte	roles	in	metabolic	dysfunction:	of	men	and	mice',	Trends	in	endocrinology	and	metabolism:	TEM,	26:	91-100.	
		 51	
Iwamoto,	Y.,	F.	Nishimura,	M.	Nakagawa,	H.	Sugimoto,	K.	Shikata,	H.	Makino,	T.	Fukuda,	T.	Tsuji,	M.	Iwamoto,	and	Y.	Murayama.	2001.	'The	effect	of	antimicrobial	periodontal	treatment	on	circulating	tumor	necrosis	factor-alpha	and	glycated	hemoglobin	level	in	patients	with	type	2	diabetes',	Journal	
of	periodontology,	72:	774-8.	Iwasaki,	M.,	M.	Sato,	K.	Minagawa,	M.	C.	Manz,	A.	Yoshihara,	and	H.	Miyazaki.	2015.	'Longitudinal	relationship	between	metabolic	syndrome	and	periodontal	disease	among	Japanese	adults	aged	>/=70	years:	the	Niigata	Study',	J	
Periodontol,	86:	491-8.	Jagannathan,	M.,	M.	McDonnell,	Y.	Liang,	H.	Hasturk,	J.	Hetzel,	D.	Rubin,	A.	Kantarci,	T.	E.	Van	Dyke,	L.	M.	Ganley-Leal,	and	B.	S.	Nikolajczyk.	2010.	'Toll-like	receptors	regulate	B	cell	cytokine	production	in	patients	with	diabetes',	
Diabetologia,	53:	1461-71.	Jagannathan-Bogdan,	M.,	M.	E.	McDonnell,	H.	Shin,	Q.	Rehman,	H.	Hasturk,	C.	M.	Apovian,	and	B.	S.	Nikolajczyk.	2011.	'Elevated	proinflammatory	cytokine	production	by	a	skewed	T	cell	compartment	requires	monocytes	and	promotes	inflammation	in	type	2	diabetes',	Journal	of	immunology,	186:	1162-72.	Jura,	J.,	P.	Wegrzyn,	M.	Korostynski,	K.	Guzik,	M.	Oczko-Wojciechowska,	M.	Jarzab,	M.	Kowalska,	M.	Piechota,	R.	Przewlocki,	and	A.	Koj.	2008.	'Identification	of	interleukin-1	and	interleukin-6-responsive	genes	in	human	monocyte-derived	macrophages	using	microarrays',	Biochimica	et	biophysica	acta,	1779:	383-9.	Kawai,	T.,	T.	Matsuyama,	Y.	Hosokawa,	S.	Makihira,	M.	Seki,	N.	Y.	Karimbux,	R.	B.	Goncalves,	P.	Valverde,	S.	Dibart,	Y.	P.	Li,	L.	A.	Miranda,	C.	W.	Ernst,	Y.	Izumi,	and	M.	A.	Taubman.	2006.	'B	and	T	lymphocytes	are	the	primary	sources	of	RANKL	in	the	bone	resorptive	lesion	of	periodontal	disease',	The	American	
journal	of	pathology,	169:	987-98.	Khaw,	K.	T.,	N.	Wareham,	S.	Bingham,	R.	Luben,	A.	Welch,	and	N.	Day.	2004.	'Association	of	hemoglobin	A1c	with	cardiovascular	disease	and	mortality	in	adults:	the	European	prospective	investigation	into	cancer	in	Norfolk',	Annals	
of	internal	medicine,	141:	413-20.	Kim,	E.	J.,	B.	H.	Jin,	and	K.	H.	Bae.	2011.	'Periodontitis	and	obesity:	a	study	of	the	Fourth	Korean	National	Health	and	Nutrition	Examination	Survey',	Journal	of	
periodontology,	82:	533-42.	Kim,	Y.	H.,	B.	H.	Choi,	H.	G.	Cheon,	and	M.	S.	Do.	2009.	'B	cell	activation	factor	(BAFF)	is	a	novel	adipokine	that	links	obesity	and	inflammation',	Experimental	&	
molecular	medicine,	41:	208-16.	Kindle,	L.,	L.	Rothe,	M.	Kriss,	P.	Osdoby,	and	P.	Collin-Osdoby.	2006.	'Human	microvascular	endothelial	cell	activation	by	IL-1	and	TNF-alpha	stimulates	the	adhesion	and	transendothelial	migration	of	circulating	human	CD14+	monocytes	that	develop	with	RANKL	into	functional	osteoclasts',	Journal	of	
		 52	
bone	and	mineral	research	:	the	official	journal	of	the	American	Society	for	
Bone	and	Mineral	Research,	21:	193-206.	Kinney,	J.	S.,	T.	Morelli,	M.	Oh,	T.	M.	Braun,	C.	A.	Ramseier,	J.	V.	Sugai,	and	W.	V.	Giannobile.	2014.	'Crevicular	fluid	biomarkers	and	periodontal	disease	progression',	Journal	of	clinical	periodontology,	41:	113-20.	Kolls,	J.	K.,	and	A.	Linden.	2004.	'Interleukin-17	family	members	and	inflammation',	
Immunity,	21:	467-76.	Kristiansen,	O.	P.,	and	T.	Mandrup-Poulsen.	2005.	'Interleukin-6	and	diabetes:	the	good,	the	bad,	or	the	indifferent?',	Diabetes,	54	Suppl	2:	S114-24.	Kwak,	H.	B.,	S.	W.	Lee,	H.	M.	Jin,	H.	Ha,	S.	H.	Lee,	S.	Takeshita,	S.	Tanaka,	H.	M.	Kim,	H.	H.	Kim,	and	Z.	H.	Lee.	2005.	'Monokine	induced	by	interferon-gamma	is	induced	by	receptor	activator	of	nuclear	factor	kappa	B	ligand	and	is	involved	in	osteoclast	adhesion	and	migration',	Blood,	105:	2963-9.	Lalla,	E.,	S.	Kaplan,	J.	Yang,	G.	A.	Roth,	P.	N.	Papapanou,	and	S.	Greenberg.	2007.	'Effects	of	periodontal	therapy	on	serum	C-reactive	protein,	sE-selectin,	and	tumor	necrosis	factor-alpha	secretion	by	peripheral	blood-derived	macrophages	in	diabetes.	A	pilot	study',	Journal	of	periodontal	research,	42:	274-82.	Larsen,	C.	M.,	M.	Faulenbach,	A.	Vaag,	J.	A.	Ehses,	M.	Y.	Donath,	and	T.	Mandrup-Poulsen.	2009.	'Sustained	effects	of	interleukin-1	receptor	antagonist	treatment	in	type	2	diabetes',	Diabetes	care,	32:	1663-8.	Lee,	M.	K.,	M.	Ide,	P.	Y.	Coward,	and	R.	F.	Wilson.	2008.	'Effect	of	ultrasonic	debridement	using	a	chlorhexidine	irrigant	on	circulating	levels	of	lipopolysaccharides	and	interleukin-6',	Journal	of	clinical	periodontology,	35:	415-9.	Liao,	W.,	J.	X.	Lin,	and	W.	J.	Leonard.	2013.	'Interleukin-2	at	the	crossroads	of	effector	responses,	tolerance,	and	immunotherapy',	Immunity,	38:	13-25.	Liu,	Y.	C.,	U.	H.	Lerner,	and	Y.	T.	Teng.	2010.	'Cytokine	responses	against	periodontal	infection:	protective	and	destructive	roles',	Periodontology	2000,	52:	163-206.	Loos,	B.	G.,	J.	Craandijk,	F.	J.	Hoek,	P.	M.	Wertheim-van	Dillen,	and	U.	van	der	Velden.	2000.	'Elevation	of	systemic	markers	related	to	cardiovascular	diseases	in	the	peripheral	blood	of	periodontitis	patients',	Journal	of	periodontology,	71:	1528-34.	Losche,	W.,	F.	Karapetow,	A.	Pohl,	C.	Pohl,	and	T.	Kocher.	2000.	'Plasma	lipid	and	blood	glucose	levels	in	patients	with	destructive	periodontal	disease',	Journal	
of	clinical	periodontology,	27:	537-41.	Maedler,	K.,	P.	Sergeev,	J.	A.	Ehses,	Z.	Mathe,	D.	Bosco,	T.	Berney,	J.	M.	Dayer,	M.	Reinecke,	P.	A.	Halban,	and	M.	Y.	Donath.	2004.	'Leptin	modulates	beta	cell	expression	of	IL-1	receptor	antagonist	and	release	of	IL-1beta	in	human	islets',	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	
America,	101:	8138-43.	
		 53	
Maedler,	K.,	P.	Sergeev,	F.	Ris,	J.	Oberholzer,	H.	I.	Joller-Jemelka,	G.	A.	Spinas,	N.	Kaiser,	P.	A.	Halban,	and	M.	Y.	Donath.	2002.	'Glucose-induced	beta	cell	production	of	IL-1beta	contributes	to	glucotoxicity	in	human	pancreatic	islets',	The	Journal	of	clinical	investigation,	110:	851-60.	Mahamed,	D.	A.,	A.	Marleau,	M.	Alnaeeli,	B.	Singh,	X.	Zhang,	J.	M.	Penninger,	and	Y.	T.	Teng.	2005.	'G(-)	anaerobes-reactive	CD4+	T-cells	trigger	RANKL-mediated	enhanced	alveolar	bone	loss	in	diabetic	NOD	mice',	Diabetes,	54:	1477-86.	Mauri,	C.,	D.	Gray,	N.	Mushtaq,	and	M.	Londei.	2003.	'Prevention	of	arthritis	by	interleukin	10-producing	B	cells',	The	Journal	of	experimental	medicine,	197:	489-501.	Mayer,	A.,	D.	Debuisson,	S.	Denanglaire,	F.	Eddahri,	L.	Fievez,	M.	Hercor,	E.	Triffaux,	M.	Moser,	F.	Bureau,	O.	Leo,	and	F.	Andris.	2014.	'Antigen	presenting	cell-derived	IL-6	restricts	Th2-cell	differentiation',	European	journal	of	
immunology,	44:	3252-62.	Mealey,	B.	L.	2006.	'Periodontal	disease	and	diabetes.	A	two-way	street',	Journal	of	
the	American	Dental	Association,	137	Suppl:	26S-31S.	Mohamed-Ali,	V.,	S.	Goodrick,	A.	Rawesh,	D.	R.	Katz,	J.	M.	Miles,	J.	S.	Yudkin,	S.	Klein,	and	S.	W.	Coppack.	1997.	'Subcutaneous	adipose	tissue	releases	interleukin-6,	but	not	tumor	necrosis	factor-alpha,	in	vivo',	The	Journal	of	clinical	
endocrinology	and	metabolism,	82:	4196-200.	Mosmann,	T.	R.,	and	R.	L.	Coffman.	1989.	'TH1	and	TH2	cells:	different	patterns	of	lymphokine	secretion	lead	to	different	functional	properties',	Annual	review	
of	immunology,	7:	145-73.	Musacchio,	E.,	C.	Valvason,	C.	Botsios,	F.	Ostuni,	A.	Furlan,	R.	Ramonda,	V.	Modesti,	L.	Sartori,	and	L.	Punzi.	2009.	'The	tumor	necrosis	factor-{alpha}-blocking	agent	infliximab	inhibits	interleukin	1beta	(IL-1beta)	and	IL-6	gene	expression	in	human	osteoblastic	cells',	The	Journal	of	rheumatology,	36:	1575-9.	Nakajima,	T.,	K.	Ueki-Maruyama,	T.	Oda,	Y.	Ohsawa,	H.	Ito,	G.	J.	Seymour,	and	K.	Yamazaki.	2005.	'Regulatory	T-cells	infiltrate	periodontal	disease	tissues',	
Journal	of	dental	research,	84:	639-43.	Nesse,	W.,	F.	Abbas,	I.	van	der	Ploeg,	F.	K.	Spijkervet,	P.	U.	Dijkstra,	and	A.	Vissink.	2008.	'Periodontal	inflamed	surface	area:	quantifying	inflammatory	burden',	
Journal	of	clinical	periodontology,	35:	668-73.	Nishimura,	F.,	Y.	Iwamoto,	J.	Mineshiba,	A.	Shimizu,	Y.	Soga,	and	Y.	Murayama.	2003.	'Periodontal	disease	and	diabetes	mellitus:	the	role	of	tumor	necrosis	factor-alpha	in	a	2-way	relationship',	Journal	of	periodontology,	74:	97-102.	Nishimura,	S.,	I.	Manabe,	M.	Nagasaki,	K.	Eto,	H.	Yamashita,	M.	Ohsugi,	M.	Otsu,	K.	Hara,	K.	Ueki,	S.	Sugiura,	K.	Yoshimura,	T.	Kadowaki,	and	R.	Nagai.	2009.	'CD8+	effector	T	cells	contribute	to	macrophage	recruitment	and	adipose	tissue	inflammation	in	obesity',	Nature	medicine,	15:	914-20.	Novaes,	A.	B.,	Jr.,	F.	G.	Gutierrez,	and	A.	B.	Novaes.	1996.	'Periodontal	disease	progression	in	type	II	non-insulin-dependent	diabetes	mellitus	patients	
		 54	
(NIDDM).	Part	I--Probing	pocket	depth	and	clinical	attachment',	Brazilian	
dental	journal,	7:	65-73.	Onal,	M.,	J.	Xiong,	X.	Chen,	J.	D.	Thostenson,	M.	Almeida,	S.	C.	Manolagas,	and	C.	A.	O'Brien.	2012.	'Receptor	activator	of	nuclear	factor	kappaB	ligand	(RANKL)	protein	expression	by	B	lymphocytes	contributes	to	ovariectomy-induced	bone	loss',	The	Journal	of	biological	chemistry,	287:	29851-60.	Onishi,	R.	M.,	and	S.	L.	Gaffen.	2010.	'Interleukin-17	and	its	target	genes:	mechanisms	of	interleukin-17	function	in	disease',	Immunology,	129:	311-21.	Osborn,	O.,	S.	E.	Brownell,	M.	Sanchez-Alavez,	D.	Salomon,	H.	Gram,	and	T.	Bartfai.	2008.	'Treatment	with	an	Interleukin	1	beta	antibody	improves	glycemic	control	in	diet-induced	obesity',	Cytokine,	44:	141-8.	Paz,	K.,	R.	Hemi,	D.	LeRoith,	A.	Karasik,	E.	Elhanany,	H.	Kanety,	and	Y.	Zick.	1997.	'A	molecular	basis	for	insulin	resistance.	Elevated	serine/threonine	phosphorylation	of	IRS-1	and	IRS-2	inhibits	their	binding	to	the	juxtamembrane	region	of	the	insulin	receptor	and	impairs	their	ability	to	undergo	insulin-induced	tyrosine	phosphorylation',	The	Journal	of	biological	
chemistry,	272:	29911-8.	Pene,	J.,	S.	Chevalier,	L.	Preisser,	E.	Venereau,	M.	H.	Guilleux,	S.	Ghannam,	J.	P.	Moles,	Y.	Danger,	E.	Ravon,	S.	Lesaux,	H.	Yssel,	and	H.	Gascan.	2008.	'Chronically	inflamed	human	tissues	are	infiltrated	by	highly	differentiated	Th17	lymphocytes',	Journal	of	immunology,	180:	7423-30.	Pickup,	J.	C.,	G.	D.	Chusney,	S.	M.	Thomas,	and	D.	Burt.	2000.	'Plasma	interleukin-6,	tumour	necrosis	factor	alpha	and	blood	cytokine	production	in	type	2	diabetes',	Life	sciences,	67:	291-300.	Prabhu,	A.,	B.	S.	Michalowicz,	and	A.	Mathur.	1996.	'Detection	of	local	and	systemic	cytokines	in	adult	periodontitis',	Journal	of	periodontology,	67:	515-22.	Randle,	P.	J.,	P.	B.	Garland,	C.	N.	Hales,	and	E.	A.	Newsholme.	1963.	'The	glucose	fatty-acid	cycle.	Its	role	in	insulin	sensitivity	and	the	metabolic	disturbances	of	diabetes	mellitus',	Lancet,	1:	785-9.	Saidenberg-Kermanac'h,	N.,	N.	Bessis,	D.	Lemeiter,	M.	C.	de	Vernejoul,	M.	C.	Boissier,	and	M.	Cohen-Solal.	2004.	'Interleukin-4	cellular	gene	therapy	and	osteoprotegerin	decrease	inflammation-associated	bone	resorption	in	collagen-induced	arthritis',	Journal	of	clinical	immunology,	24:	370-8.	Salvi,	G.	E.,	J.	D.	Beck,	and	S.	Offenbacher.	1998.	'PGE2,	IL-1	beta,	and	TNF-alpha	responses	in	diabetics	as	modifiers	of	periodontal	disease	expression',	Annals	
of	periodontology	/	the	American	Academy	of	Periodontology,	3:	40-50.	Salvi,	G.	E.,	M.	Kandylaki,	A.	Troendle,	G.	R.	Persson,	and	N.	P.	Lang.	2005.	'Experimental	gingivitis	in	type	1	diabetics:	a	controlled	clinical	and	microbiological	study',	Journal	of	clinical	periodontology,	32:	310-6.	Santos,	V.	R.,	J.	A.	Lima,	T.	E.	Goncalves,	M.	F.	Bastos,	L.	C.	Figueiredo,	J.	A.	Shibli,	and	P.	M.	Duarte.	2010.	'Receptor	activator	of	nuclear	factor-kappa	B	ligand/osteoprotegerin	ratio	in	sites	of	chronic	periodontitis	of	subjects	with	
		 55	
poorly	and	well-controlled	type	2	diabetes',	Journal	of	periodontology,	81:	1455-65.	Sasaki,	H.,	Y.	Okamatsu,	T.	Kawai,	R.	Kent,	M.	Taubman,	and	P.	Stashenko.	2004.	'The	interleukin-10	knockout	mouse	is	highly	susceptible	to	Porphyromonas	gingivalis-induced	alveolar	bone	loss',	Journal	of	periodontal	research,	39:	432-41.	Sauter,	N.	S.,	F.	T.	Schulthess,	R.	Galasso,	L.	W.	Castellani,	and	K.	Maedler.	2008.	'The	antiinflammatory	cytokine	interleukin-1	receptor	antagonist	protects	from	high-fat	diet-induced	hyperglycemia',	Endocrinology,	149:	2208-18.	Savill,	J.,	I.	Dransfield,	C.	Gregory,	and	C.	Haslett.	2002.	'A	blast	from	the	past:	clearance	of	apoptotic	cells	regulates	immune	responses',	Nature	reviews.	
Immunology,	2:	965-75.	Saxlin,	T.,	P.	Ylostalo,	L.	Suominen-Taipale,	S.	Mannisto,	and	M.	Knuuttila.	2011.	'Association	between	periodontal	infection	and	obesity:	results	of	the	Health	2000	Survey',	Journal	of	clinical	periodontology,	38:	236-42.	Sbordone,	L.,	L.	Ramaglia,	A.	Barone,	R.	N.	Ciaglia,	and	V.	J.	Iacono.	1998.	'Periodontal	status	and	subgingival	microbiota	of	insulin-dependent	juvenile	diabetics:	a	3-year	longitudinal	study',	Journal	of	periodontology,	69:	120-8.	Seymour,	G.	J.,	E.	Gemmell,	L.	J.	Walsh,	and	R.	N.	Powell.	1988.	'Immunohistological	analysis	of	experimental	gingivitis	in	humans',	Clinical	and	experimental	
immunology,	71:	132-7.	Shaul,	M.	E.,	G.	Bennett,	K.	J.	Strissel,	A.	S.	Greenberg,	and	M.	S.	Obin.	2010.	'Dynamic,	M2-like	remodeling	phenotypes	of	CD11c+	adipose	tissue	macrophages	during	high-fat	diet--induced	obesity	in	mice',	Diabetes,	59:	1171-81.	Shin,	J.	H.,	D.	W.	Shin,	and	M.	Noh.	2009.	'Interleukin-17A	inhibits	adipocyte	differentiation	in	human	mesenchymal	stem	cells	and	regulates	pro-inflammatory	responses	in	adipocytes',	Biochemical	pharmacology,	77:	1835-44.	Simpson,	T.	C.,	I.	Needleman,	S.	H.	Wild,	D.	R.	Moles,	and	E.	J.	Mills.	2010.	'Treatment	of	periodontal	disease	for	glycaemic	control	in	people	with	diabetes',	
Cochrane	Database	Syst	Rev:	CD004714.	Solinas,	G.,	C.	Vilcu,	J.	G.	Neels,	G.	K.	Bandyopadhyay,	J.	L.	Luo,	W.	Naugler,	S.	Grivennikov,	A.	Wynshaw-Boris,	M.	Scadeng,	J.	M.	Olefsky,	and	M.	Karin.	2007.	'JNK1	in	hematopoietically	derived	cells	contributes	to	diet-induced	inflammation	and	insulin	resistance	without	affecting	obesity',	Cell	
metabolism,	6:	386-97.	Soskolne,	W.	A.,	and	A.	Klinger.	2001.	'The	relationship	between	periodontal	diseases	and	diabetes:	an	overview',	Annals	of	periodontology	/	the	American	
Academy	of	Periodontology,	6:	91-8.	Strissel,	K.	J.,	Z.	Stancheva,	H.	Miyoshi,	J.	W.	Perfield,	2nd,	J.	DeFuria,	Z.	Jick,	A.	S.	Greenberg,	and	M.	S.	Obin.	2007.	'Adipocyte	death,	adipose	tissue	remodeling,	and	obesity	complications',	Diabetes,	56:	2910-8.	
		 56	
Suganami,	T.,	J.	Nishida,	and	Y.	Ogawa.	2005.	'A	paracrine	loop	between	adipocytes	and	macrophages	aggravates	inflammatory	changes:	role	of	free	fatty	acids	and	tumor	necrosis	factor	alpha',	Arteriosclerosis,	thrombosis,	and	vascular	
biology,	25:	2062-8.	Tada,	F.,	M.	Abe,	K.	Kawasaki,	T.	Miyake,	C.	Shiyi,	Y.	Hiasa,	B.	Matsuura,	and	M.	Onji.	2013.	'B	cell	activating	factor	in	obesity	is	regulated	by	oxidative	stress	in	adipocytes',	Journal	of	clinical	biochemistry	and	nutrition,	52:	120-7.	Takashiba,	S.,	M.	Takigawa,	K.	Takahashi,	F.	Myokai,	F.	Nishimura,	T.	Chihara,	H.	Kurihara,	Y.	Nomura,	and	Y.	Murayama.	1992.	'Interleukin-8	is	a	major	neutrophil	chemotactic	factor	derived	from	cultured	human	gingival	fibroblasts	stimulated	with	interleukin-1	beta	or	tumor	necrosis	factor	alpha',	Infection	and	immunity,	60:	5253-8.	Takigawa,	M.,	S.	Takashiba,	F.	Myokai,	K.	Takahashi,	H.	Arai,	H.	Kurihara,	and	Y.	Murayama.	1994.	'Cytokine-dependent	synergistic	regulation	of	interleukin-8	production	from	human	gingival	fibroblasts',	Journal	of	periodontology,	65:	1002-7.	Teeuw,	W.	J.,	V.	E.	Gerdes,	and	B.	G.	Loos.	2010.	'Effect	of	periodontal	treatment	on	glycemic	control	of	diabetic	patients:	a	systematic	review	and	meta-analysis',	
Diabetes	care,	33:	421-7.	Thorstensson,	H.,	G.	Dahlen,	and	A.	Hugoson.	1995.	'Some	suspected	periodontopathogens	and	serum	antibody	response	in	adult	long-duration	insulin-dependent	diabetics',	Journal	of	clinical	periodontology,	22:	449-58.	Tomas,	I.,	P.	Diz,	A.	Tobias,	C.	Scully,	and	N.	Donos.	2012.	'Periodontal	health	status	and	bacteraemia	from	daily	oral	activities:	systematic	review/meta-analysis',	
Journal	of	clinical	periodontology,	39:	213-28.	Tsigos,	C.,	I.	Kyrou,	E.	Chala,	P.	Tsapogas,	J.	C.	Stavridis,	S.	A.	Raptis,	and	N.	Katsilambros.	1999.	'Circulating	tumor	necrosis	factor	alpha	concentrations	are	higher	in	abdominal	versus	peripheral	obesity',	Metabolism:	clinical	and	
experimental,	48:	1332-5.	Uysal,	K.	T.,	S.	M.	Wiesbrock,	M.	W.	Marino,	and	G.	S.	Hotamisligil.	1997.	'Protection	from	obesity-induced	insulin	resistance	in	mice	lacking	TNF-alpha	function',	
Nature,	389:	610-4.	Van	der	Weijden,	G.	A.,	and	M.	F.	Timmerman.	2002.	'A	systematic	review	on	the	clinical	efficacy	of	subgingival	debridement	in	the	treatment	of	chronic	periodontitis',	Journal	of	clinical	periodontology,	29	Suppl	3:	55-71;	discussion	90-1.	Verwaerde,	C.,	A.	Delanoye,	L.	Macia,	A.	Tailleux,	and	I.	Wolowczuk.	2006.	'Influence	of	high-fat	feeding	on	both	naive	and	antigen-experienced	T-cell	immune	response	in	DO10.11	mice',	Scand	J	Immunol,	64:	457-66.	Wannamethee,	S.	G.,	G.	D.	Lowe,	A.	G.	Shaper,	A.	Rumley,	L.	Lennon,	and	P.	H.	Whincup.	2005.	'The	metabolic	syndrome	and	insulin	resistance:	relationship	to	haemostatic	and	inflammatory	markers	in	older	non-diabetic	men',	
Atherosclerosis,	181:	101-8.	
		 57	
Wilton,	J.	M.,	T.	J.	Hurst,	and	J.	A.	Sterne.	1993.	'Elevated	opsonic	activity	for	Porphyromonas	(Bacteroides)	gingivalis	in	serum	from	patients	with	a	history	of	destructive	periodontal	disease.	A	case:	control	study',	Journal	of	
clinical	periodontology,	20:	563-9.	Winer,	S.,	Y.	Chan,	G.	Paltser,	D.	Truong,	H.	Tsui,	J.	Bahrami,	R.	Dorfman,	Y.	Wang,	J.	Zielenski,	F.	Mastronardi,	Y.	Maezawa,	D.	J.	Drucker,	E.	Engleman,	D.	Winer,	and	H.	M.	Dosch.	2009.	'Normalization	of	obesity-associated	insulin	resistance	through	immunotherapy',	Nature	medicine,	15:	921-9.	Wynn,	T.	A.,	A.	Chawla,	and	J.	W.	Pollard.	2013.	'Macrophage	biology	in	development,	homeostasis	and	disease',	Nature,	496:	445-55.	Yan,	H.,	M.	Wu,	Y.	Yuan,	Z.	Z.	Wang,	H.	Jiang,	and	T.	Chen.	2014.	'Priming	of	Toll-like	receptor	4	pathway	in	mesenchymal	stem	cells	increases	expression	of	B	cell	activating	factor',	Biochemical	and	biophysical	research	communications,	448:	212-7.	Yang,	H.,	Y.	H.	Youm,	B.	Vandanmagsar,	A.	Ravussin,	J.	M.	Gimble,	F.	Greenway,	J.	M.	Stephens,	R.	L.	Mynatt,	and	V.	D.	Dixit.	2010.	'Obesity	increases	the	production	of	proinflammatory	mediators	from	adipose	tissue	T	cells	and	compromises	TCR	repertoire	diversity:	implications	for	systemic	inflammation	and	insulin	resistance',	J	Immunol,	185:	1836-45.	Zambon,	J.	J.,	H.	Reynolds,	J.	G.	Fisher,	M.	Shlossman,	R.	Dunford,	and	R.	J.	Genco.	1988.	'Microbiological	and	immunological	studies	of	adult	periodontitis	in	patients	with	noninsulin-dependent	diabetes	mellitus',	Journal	of	
periodontology,	59:	23-31.	Zuniga,	L.	A.,	W.	J.	Shen,	B.	Joyce-Shaikh,	E.	A.	Pyatnova,	A.	G.	Richards,	C.	Thom,	S.	M.	Andrade,	D.	J.	Cua,	F.	B.	Kraemer,	and	E.	C.	Butcher.	2010.	'IL-17	regulates	adipogenesis,	glucose	homeostasis,	and	obesity',	Journal	of	immunology,	185:	6947-59.	
 
		 58	
CURRICULUM VITAE 
	
	
		 59	
